Month: September 2022

System to be Utilized by the Oncology-Focused Clinic for General and Visceral SurgerySenhance Surgical System Senhance Surgical SystemRESEARCH TRIANGLE PARK, N.C., Sept. 28, 2022 (GLOBE NEWSWIRE) — Asensus Surgical, Inc. (NYSE American: ASXC), a medical device company that is digitizing the interface between the surgeon and the patient to pioneer a new era of Performance-Guided Surgery™, today announced the Clinic for General and Visceral Surgery at the St. Bernhard Hospital in Kamp-Lintfort, Germany has entered into an agreement to lease and utilize a Senhance® Surgical System. “We are excited to announce our partnership with St. Bernhard Hospital as it looks to leverage cutting edge minimally invasive surgical solutions to help improve patient outcomes. The Senhance System’s novel intelligent capabilities coupled with the...

Firm to support NAVFAC with focus on encroachment management implementation and mission readiness EDMONTON, Alberta and NEW YORK, Sept. 28, 2022 (GLOBE NEWSWIRE) — TSX, NYSE:STN Stantec, a global leader in sustainable design and engineering, has been selected by Naval Facilities Engineering Systems Command (NAVFAC) Southwest to lead multidiscipline architect-engineer and consulting services as part of a five-year, US$30 million indefinite delivery/indefinite quantity (IDIQ) single award task order contract. The IDIQ contract awarded to Stantec Government Services focuses on encroachment management implementation and mission readiness, sustainment, and compatibility services for NAVFAC, mostly at Navy and Marine Corps facilities in Southern California. Through this contract, Stantec may support additional NAVFAC areas of responsibility....

Figure 1 Map of Penedela Project Planned Drill TargetsTORONTO, Sept. 28, 2022 (GLOBE NEWSWIRE) — Western Metallica Resources Corp. (TSXV: WMS) (“Western Metallica” or the “Company”) is pleased to report the re-start of the Penedela Project drill program, following the announcement of the Vice President of Exploration appointment, which led to the reprioritization of drill targets and advanced program planning. The current phase of the 2,000-metre diamond drilling program, initially announced in May 2022, will focus on significantly stepping out along trend from previous targets with the aim of testing underexplored regions of the property. This phase of the Company’s drill program at Penedela intends to prove the property has the potential to host a million-ounce resource by prospectively confirming higher grades and wider intercepts,...

– Completed Phase 1 clinical trial establishes gavo-cel monotherapy as the first anti-mesothelin cell therapy to demonstrate tolerability and clinical benefit– Second RECIST partial response in ovarian cancer supports broad potential of gavo-cel– Consistent tumor regression in 28 of 30 (93%) evaluable patients with disease control rate of 77%– Progression-free survival of 5.6 months and overall survival of 11.2 months suggest durability of benefit in mesothelioma– Phase 2 portion of trial underway implementing multiple approaches to further improve clinical outcomes– TCR2 to host a conference call on Wednesday, September 28, 2022 at 8:00a.m. ET CAMBRIDGE, Mass., Sept. 28, 2022 (GLOBE NEWSWIRE) — TCR2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage cell therapy company with a pipeline of novel...